SCHEMBL21725481

SCHEMBL21725481

CC(C)c1ccc(Cl)cc1N1CC[C@H](CN)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.43
BPTF Q12830 1/20 0.42
IRAK4 Q9NWZ3 2/20 0.40
NOTUM Q6P988 2/20 0.39
CNR1 P21554 1/20 0.38
ACACB O00763 2/20 0.37
ALDH1A1 P00352 2/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
MAOB P27338 1/20 0.36
HTR6 P50406 1/20 0.36
PTPN11 Q06124 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
TOP1 P11387 1/20 0.34
HTT P42858 1/20 0.34
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
PIM2 Q9P1W9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725460 1.00 HRH4 (0.43) HRH4BPTFIRAK4NOTUMCNR1
SCHEMBL21725534 0.85 BPTF (0.43) BPTFIRAK4ACACBALDH1A1HTR2A
SCHEMBL21725466 0.84 BPTF (0.54) BPTFACACBTOP1HTTPIM1
SCHEMBL21725457 0.82 PIM1 (0.47) HRH4IRAK4NOTUMACACBALDH1A1
SCHEMBL23251388 0.82 ALDH1A1 (0.55) HRH4BPTFIRAK4NOTUMCNR1
SCHEMBL23251403 0.82 ALDH1A1 (0.55) HRH4BPTFIRAK4NOTUMCNR1
SCHEMBL22193242 0.81 HRH4 (0.44) HRH4BPTFIRAK4NOTUMCNR1
SCHEMBL22193241 0.81 HRH4 (0.44) HRH4BPTFIRAK4NOTUMCNR1
SCHEMBL21725494 0.81 LIPG (0.43) BPTFACACB
SCHEMBL21725436 0.79 PAK4 (0.41) NOTUMALDH1A1HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-09-08 US disclosed
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-07-09 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HRH4 355/4885BPTF 2226/4885IRAK4 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.